US Edition
News from Clinical Trials Arena
If you want to know if Clinical Trials Arena is credible or reliable, look no further. We rank Clinical Trials Arena as Unknown factuality. Find out more about our methodology here.
Information about Clinical Trials Arena
Where is Clinical Trials Arena located?Clinical Trials Arena's WebsiteMedia Bias Ratings
Do you disagree?
Edit bias
Learn more about Media Bias Ratings.
Factuality
Learn more about Factuality Ratings
Reveal Factuality Ratings by upgrading to a Premium account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Ownership
Learn more about Ownership categories
Reveal Ownership Data by upgrading to a Vantage account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Top Clinical Trials Arena News
Eli Lilly · IndianapolisIn addition to meeting the primary endpoint of non-inferiority for overall response rate (ORR) in the BRUIN CLL-314 study, pirtobrutinib achieved a numerically higher ORR of 87.0% compared to 78.5% for ibrutinib in the intent-to-treat (ITT) populationSee the Story
Lilly's Jaypirca (Pirtobrutinib) Met Its Primary Endpoint in First-of-Its-Kind, Head-to-Head Phase 3 Study versus Imbruvica (Ibrutinib)
65% Center coverage: 26 sources
WegovyMove over Ozempic, Wegovy, Mounjaro and Zepbound — Eli Lilly says another contender may be on the way. The pharmaceutical giant announced encouraging results from a Phase 3 clinical trial of its experimental weight loss drug retatrutide, showing levels of weight loss that could rival — or exceed — existing blockbuster treatments. What the study found According to Eli Lilly, patients taking retatrutide lost nearly 30% of their body weight over 68…See the Story
Eli Lilly Touts Strong Results of New Experimental Weight Loss Drug Retatrutide
50% Center coverage: 4 sources
VaccinesMany medical organizations and frontline health care providers are grappling with a challenge they haven't had to face in many years: how to protect newborns against hepatitis B.See the Story
CDC Vaccine Advisers' New Focus on Hepatitis B Tests in Pregnancy Is Not Enough, some Doctors Warn
50% Center coverage: 4 sources
